Virtual Library

Start Your Search

A. El Bastawisy

Author of

  • +

    Poster Display Session (ID 63)

    • Event: ELCC 2017
    • Type: Poster Display Session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 5/07/2017, 12:30 - 13:00, Hall 1
    • +

      160P - BAP1 in advanced sporadic malignant pleural mesothelioma (ID 304)

      12:30 - 13:00  |  Author(s): A. El Bastawisy

      • Abstract

      BAP1 mutation has been previously described in familial malignant pleural mesothelioma (MPM), however a little is known about its role in sporadic MPM.

      This is a prospective study including all eligible cases of MPM presenting to NCI, Cairo University, Egypt during the years 2013-2016. BAP1 analysis was done by PCR. Patients received first line chemotherapy (Pemetrexed/platinum). Primary objective was to evaluate the rate of BAP1 mutation in MPM, secondary objectives: To evaluate the correlation of BAP1 mutation and objective response rate (ORR), progression free survival (PFS) and overall survival (OS) in advanced MPM.

      Among 120 cases, 38.5% showed positive BAP1 mutation.56.5% in the mutated group showed overall clinical benefit (CR+PR+SD) versus 46.2% in the wild group. (P = 0.34). One year PFS in the mutated group was 50.5% versus 38.5% in the wild group. (P = 0.31). One-year OS in the mutated group was 54.5% versus 47.6% in the wild group. (P = 0.67).

      BAP1 mutation is present in high frequency in a Caucasian population however it was not associated with clinical outcome after first line platinum based chemotherapy.

      Clinical trial identification:

      Legal entity responsible for the study:
      National Cancer Institute and Faculty of Pharmacy, Cairo University, Egypt

      National Cancer Institute and Faculty of Pharmacy, Cairo University, Egypt

      All authors have declared no conflicts of interest.